Details

Autor(en) / Beteiligte

• Bassler, Dirk
• Plavka, Richard
• Shinwell, Eric S
• Hallman, Mikko
• Jarreau, Pierre-Henri
• Carnielli, Virgilio
• Van den Anker, Johannes N
• Meisner, Christoph
• Engel, Corinna
• Schwab, Matthias
• Halliday, Henry L
• Poets, Christian F

Titel

Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia

Ist Teil von

• The New England journal of medicine, 2015-10, Vol.373 (16), p.1497-1506

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• The risk of bronchopulmonary dysplasia was significantly lower, and the risk of death slightly but not significantly higher, among extremely preterm infants who were randomly assigned to inhaled budesonide soon after birth than among those assigned to placebo. About one half of preterm infants (gestational age, <28 weeks) have bronchopulmonary dysplasia, 1 , 2 which is a major cause of early death. 1 , 3 Infants with bronchopulmonary dysplasia who survive have increased risks of neurodevelopmental impairment 4 and respiratory problems later in life. 5 , 6 Bronchopulmonary dysplasia results from ongoing lung injury and simultaneous repair 7 , 8 ; inflammation related to chorioamnionitis, postnatal infections, or iatrogenic causes (such as the use of ventilation or oxygen) contributes to lung fibrosis and arrested lung development. 7 , 9 Systemic glucocorticoids have been shown to reduce the incidence of bronchopulmonary dysplasia, but they may cause short-term and long-term adverse . . .